Abstract:Breast cancer (BC) is the most common type of cancer in women and the number of new cases in the US is still increasing each year. Triple-negative breast cancer (TNBC), which comprises 15–20% of all breast cancer, is a heterogeneous disease and is considered the most aggressive type of breast cancer due to the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions for treatments. Traditional chemotherapy is the standard protocol for the treatment of TNBC. Toxicity and multidrug resistance are major drawbacks to chemotherapy. The lack of molecular targets and poor prognosis for TNBC prompts an urgent need to discover novel therapeutic strategies to improve clinical outcomes and quality of life for patients. Photodynamic therapy (PDT) or light treatment is a binary anti-cancer procedure that uses a photosensitizer (PS) that, upon light activation, produces cytotoxic oxygen species, destroying tumor cells. PDT is minimally invasive and can be repeated a few times without accumulating significant toxicity in the surrounding tissues. The primary goal of this study was to investigate in vitro photodynamic chemotherapy as a ternary combination therapy using our synthesized photosensitizers (chlorin–vitamin conjugates and their corresponding indium complexes) co-treated with known chemotherapeutic agents (taxol, doxorubicin, cisplatin, fluorouracil, or methotrexate) in the presence of light and determine the optimum conditions as a pre-clinical study of an enhanced tumoricidal effect against TNBC. Our results indicated that the best combination for an effective chemophotodynamic effect involves a ternary treatment of the indium complex of the chlorin–lipoic acid conjugate (InCLA) co-treated with taxol, which exhibited strong synergism at the nanomolar concentration when combined in the presence of visible light irradiation. Other ternary combinations containing taxol with a synergistic anti-tumor effect against TNBC include chlorin–pantothenic acid (CPA) and chlorin–biotin (CBTN) conjugates. Several other ternary combinations containing InCLA, CBTN, and CPA with either cisplatin, fluorouracil, or methotrexate were identified to generate a synergistic or additive effect. The light dosage remained constant, but the dosages of photosensitizers and chemotherapy drugs were varied to obtain the lowest possible concentration for the desired effect. The synergistic, additive or antagonistic effects of the drug combinations were determined based on the Chou–Talalay method, with InCLA–taxol having the lowest combination index (CI) of 0.25. Fluorescence and transmission electron microscopy (TEM) images provided evidence of apoptosis as the preferred mode of cell death. Our study demonstrated the combination of PDT and chemotherapy as a potential treatment option for TNBC patients.

Potential therapeutic efficacy of Photodynamic Therapy on triple negative breast cancer in hormonal microenvironment

Potential therapeutic efficacy of Photodynamic Therapy on female hormonal-dependent cancers in a hormonal simulated microenvironment

The therapeutic efficacy of 5-ALA based photodynamic therapy and chemotherapy combination in triple negative breast cancer cells

Metformin and oxyphotodynamic therapy as a novel treatment approach for triple-negative breast cancer.

Synergistic Effects of Photodynamic Therapy and Chemotherapy: Activating the Intrinsic/extrinsic Apoptotic Pathway of Anoikis for Triple-Negative Breast Cancer Treatment

The Effect of NF-κB Deactivation on Cancer Cell Response to ALA Mediated Photodynamic Therapy

Light-inducible nanodrug-mediated photodynamic and anti-apoptotic synergy for enhanced immunotherapy in triple-negative breast cancer

Drug Self‐Delivery Nanocubes Enhance O2‐Economized Photodynamic‐Immunotherapy of Triple‐Negative Breast Cancer by Downregulating Wnt/β‐catenin Signaling

Tumor Microenvironment Activated and Amplified Self-Luminescent Nano Photosensitizers for Efficient Treatment of Triple Negative Breast Cancer

Injectable Alginate Complex Hydrogel Loaded with Dual-Drug Nanovectors Offers Effective Photochemotherapy against Triple-Negative Breast Cancer

Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer

Abstract 5743: Liposome platform enables X-ray induced photodynamic therapy treatment against human triple negative breast cancer cells

Tumor oxygenation nanoliposomes promote deep photodynamic therapy for triple-negative breast cancer

Dual-Targeting Tumor and Subcellular Endoplasmic Reticulum via AgPPIX-based Janus Nanoparticles for Photodynamic/Immunotherapy against TNBC

Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles.

Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer

Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination Treatment for Triple-Negative Breast Cancer

Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals

A dual-sensitive nanoparticle-mediated deepening synergistic therapy strategy involving DNA damage and ICD stimuli to treat triple-negative breast cancer

Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles

A Multifunctional Nanoplatform for Ultrasound Imaging and Autophagy Inhibition to Enhance Photothermal Treatment of Triple Negative Breast Cancer